B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body (minimal residual disease)...read more
B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body (minimal residual disease)...read more
BLINCYTO® is a prescription medicine used to treat BCP-ALL in adults and children one month or older. It is an immunotherapy, not a chemotherapy. An immunotherapy is a type of treatment that engages with parts of your body’s own immune system to fight diseases such as cancer.1,2
Cancer can often hide from treatments, making it hard to get rid of all cancer cells. Even after reaching remission with chemotherapy, a relatively small number of cancer cells can remain in your body that cannot be detected by traditional testing. This is called minimal residual disease, or MRD.3
There are now very sensitive and reliable tests to detect MRD, and it is important to get tested for MRD even after achieving remission. Ask your doctor if an MRD test is right for your child.1,3
If your child* is in remission but tests positive for MRD, BLINCYTO® can help.1
BLINCYTO® is also approved for:1
The use of BLINCYTO® after initial treatment in children with Ph(–) BCP-ALL is supported by data from the following studies:
Ask your child’s doctor if BLINCYTO® is right for treating their ALL.
*Older than one month of age.1
During treatment with BLINCYTO®, your health care provider will check for symptoms, which can be suggestive of serious side effects that can be severe, life-threatening, or lead to death.
It is also important to notify your health care provider of any side effects you may be having. If certain side effects are observed, your health care provider may change the dose, or delay, or completely stop BLINCYTO® treatment.
Serious side effects that can occur during BLINCYTO® treatment include cytokine release syndrome (CRS), infusion reactions, and neurologic problems.
People with Down Syndrome over the age of 10 years may have a higher risk of seizures with BLINCYTO® treatment.
These are not all the possible side effects of BLINCYTO®.
Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your health care provider right away if you develop an infection or fever, or if you have any side effects that bother you or do not go away.
What is the most important information I should know about BLINCYTO®?
Who should not receive BLINCYTO®?
Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:
What should I avoid while receiving BLINCYTO®?
BLINCYTO® may cause serious side effects, including:
The most common side effects
These are not all the possible side effects of BLINCYTO®.
Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please read the accompanying Medication Guide before you or your child receives BLINCYTO® and before each BLINCYTO® infusion and discuss it with your doctor.
Please see BLINCYTO® full Prescribing Information, including BOXED WARNINGS and Medication Guide.
What is the most important information I should know about BLINCYTO®?
References: 1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. National Cancer Institute. NCI dictionary of cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed June 25, 2024. 3. Brüggemann M, Gökbuget N, Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol. 2012;39:47-57. 4. Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA. 2021;325:833-842. 5. BLINCYTO® (blinatumomab) medication guide, Amgen.